Ajikumar B Aryangat and John E Gerich, ‘Type 2 Diabetes: Postprandial Hyperglycemia and Increased Cardiovascular Risk’ (2010) 6 Vascular Health and Risk Management <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860446/>
Anderson B, Funnell M, and American Diabetes Association, The Art of Empowerment: Stories and Strategies for Diabetes Educators (2nd ed, American Diabetes Association 2005)
Ashwell SG and others, ‘Improved Glycaemic Control with Insulin Glargine plus Insulin Lispro: A Multicentre, Randomized, Cross-over Trial in People with Type 1 Diabetes’ (2006) 23 Diabetic Medicine 285
Bergenstal RM and others, ‘Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes’ (2010) 363 New England Journal of Medicine 311
Bolinder J and others, ‘Novel Glucose-Sensing Technology and Hypoglycaemia in Type 1 Diabetes: A Multicentre, Non-Masked, Randomised Controlled Trial’ (2016) 388 The Lancet 2254
Bretzel RG and others, ‘Once-Daily Basal Insulin Glargine versus Thrice-Daily Prandial Insulin Lispro in People with Type 2 Diabetes on Oral Hypoglycaemic Agents (APOLLO): An Open Randomised Controlled Trial’ (2008) 371 The Lancet 1073
Buse JB and others, ‘Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes’ (2011) 154 Annals of Internal Medicine
Carver C, ‘Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes’ (2006) 32 The Diabetes Educator 910
Crasto W and others, ‘Insulin U-500 in Severe Insulin Resistance in Type 2 Diabetes Mellitus’ (2009) 85 Postgraduate Medical Journal 219
Daly H and others, ‘Development of a Self-Management Education Module for Those with Type 2 Diabetes on Injectable Therapies’ (2015) 32 Practical Diabetes 305
Davies M and others, ‘Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of Two Treatment Algorithms Using Insulin Glargine’ (2005) 28 Diabetes Care 1282
Davies MJ and others, ‘Exenatide Compared with Long-Acting Insulin to Achieve Glycaemic Control with Minimal Weight Gain in Patients with Type 2 Diabetes: Results of the Helping Evaluate Exenatide in Patients with Diabetes Compared with Long-Acting Insulin (HEELA) Study’ (2009) 11 Diabetes, Obesity and Metabolism 1153
——, ‘Exenatide Compared with Long-Acting Insulin to Achieve Glycaemic Control with Minimal Weight Gain in Patients with Type 2 Diabetes: Results of the Helping Evaluate Exenatide in Patients with Diabetes Compared with Long-Acting Insulin (HEELA) Study’ (2009) 11 Diabetes, Obesity and Metabolism 1153
——, ‘Impact of Baseline HbA1c, Diabetes Duration and BMI on Clinical Outcomes in the LixiLan-O Trial Testing iGlarLixi (Insulin Glargine/Lixisenatide Titratable Fixed-Ratio Combination) versus Insulin Glargine and Lixisenatide Monocomponents’ [2017] Diabetes, Obesity and Metabolism
Diamant M and others, ‘Once Weekly Exenatide Compared with Insulin Glargine Titrated to Target in Patients with Type 2 Diabetes (DURATION-3): An Open-Label Randomised Trial’ (2010) 375 The Lancet 2234
Evans M and others, ‘A Review of Modern Insulin Analogue Pharmacokinetic and Pharmacodynamic Profiles in Type 2 Diabetes: Improvements and Limitations’ (2011) 13 Diabetes, Obesity and Metabolism 677
Frandsen CSS and Madsbad S, ‘Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors as an Add-on to Insulin Treatment in Patients with Type 2 Diabetes: A Review’ (2014) 31 Diabetic Medicine 1293
Funnell MM, ‘Overcoming Barriers to the Initiation of Insulin Therapy’ (2007) 25 Clinical Diabetes 36
Garber AJ and others, ‘Attainment of Glycaemic Goals in Type 2 Diabetes with Once-, Twice-, or Thrice-Daily Dosing with Biphasic Insulin Aspart 70/30 (The 1-2-3 Study)’ (2006) 8 Diabetes, Obesity and Metabolism 58
Garber AJ and others, ‘Premixed Insulin Treatment for Type 2 Diabetes: Analogue or Human?’ (2007) 9 Diabetes, Obesity and Metabolism 630
Gough SCL, ‘A Review of Human and Analogue Insulin Trials’ (2007) 77 Diabetes Research and Clinical Practice 1
——, ‘Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes’ (2013) 36 Diabetes Care 2536
Gururaj Setty S and others, ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’ (2016) 92 Postgraduate Medical Journal 152
——, ‘New Insulins and Newer Insulin Regimens: A Review of Their Role in Improving Glycaemic Control in Patients with Diabetes’ (2016) 92 Postgraduate Medical Journal 152
Heller SR and others, ‘Hypoglycaemia with Insulin Aspart: A Double-Blind, Randomised, Crossover Trial in Subjects with Type 1 Diabetes’ (2004) 21 Diabetic Medicine 769
Hermansen K and others, ‘A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes’ (2006) 29 Diabetes Care 1269
Hirsch IB and others, ‘Options for Prandial Glucose Management in Type 2 Diabetes Patients Using Basal Insulin: Addition of a Short-Acting GLP-1 Analogue versus Progression to Basal-Bolus Therapy’ (2014) 16 Diabetes, Obesity and Metabolism 206
——, ‘Options for Prandial Glucose Management in Type 2 Diabetes Patients Using Basal Insulin: Addition of a Short-Acting GLP-1 Analogue versus Progression to Basal-Bolus Therapy’ (2014) 16 Diabetes, Obesity and Metabolism 206
——, ‘Safety and Efficacy of Insulin Degludec/Insulin Aspart with Bolus Mealtime Insulin Aspart Compared with Standard Basal-Bolus Treatment in People with Type 1 Diabetes: 1-Year Results from a Randomized Clinical Trial (BOOST T1)’ (2017) 34 Diabetic Medicine 167
Holman RR and others, ‘Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes’ (2007) 357 New England Journal of Medicine 1716
Holman RR and Turner RC, ‘A Practical Guide to Basal and Prandial Insulin Therapy’ (1985) 2 Diabetic Medicine 45
Home PD, ‘The Pharmacokinetics and Pharmacodynamics of Rapid-Acting Insulin Analogues and Their Clinical Consequences’ (2012) 14 Diabetes, Obesity and Metabolism 780
Horvath K and others, ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>
——, ‘Long-Acting Insulin Analogues versus NPH Insulin (Human Isophane Insulin) for Type 2 Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>
Htike ZZ and others, ‘Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis’ [2017] Diabetes, Obesity and Metabolism
Inzucchi SE and others, ‘Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes’ (2015) 38 Diabetes Care 140
Ismail-Beigi F, ‘Glycemic Management of Type 2 Diabetes Mellitus’ (2012) 366 New England Journal of Medicine 1319
June James, ‘Safety and Insulin: Implementation of National Guidance at a Local Level’ Journal of diabetes nursing. <http://le-primo.hosted.exlibrisgroup.com/primo_library/libweb/action/openurl?ctx=&isSerivcesPage=true&rft.jtitle=Journal+of+Diabetes+Nursing&rft.aufirst=June&dscnt=2&url_ctx_fmt=null&vid=44UOLE_services_page&rft.aulast=James&institution=44UOLE&url_ver=Z39.88-2004&rft.atitle=Safety+and+insulin%3A+implementation+of+national+guidance+at+a+local+level&dstmp=1488893669239&fromLogin=true>
Khunti K and others, ‘Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study’ (2015) 38 Diabetes Care 316
L. Luzi, ‘Effect of Loss of First-Phase Insulin Secretion on Hepatic Glucose Production and Tissue Glucose Disposal in Humans’ (1989) 257 American Journal of Physiology - Endocrinology and Metabolism E241 <http://ajpendo.physiology.org/content/257/2/E241>
Leelarathna L and others, ‘Comparison of Different Insulin Pump Makes under Routine Care Conditions in Adults with Type 1 Diabetes’ (2017) 34 Diabetic Medicine 1372
Luc JC van Loon, ‘Plasma Insulin Responses after Ingestion of Different Amino Acid or Protein Mixtures with Carbohydrate’ (2000) 72 The American Journal of Clinical Nutrition 96 <http://ajcn.nutrition.org/content/72/1/96.full>
MacKinnon M, Providing Diabetes Care in General Practice: A Practical Guide to Integrated Care (4th ed, Class 2002) <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=581376>
Mäkimattila S, Nikkilä K and Yki-Järvinen H, ‘Causes of Weight Gain during Insulin Therapy with and without Metformin in Patients with Type II Diabetes Mellitus’ (1999) 42 Diabetologia 406
Malmberg K, ‘Prospective Randomised Study of Intensive Insulin Treatment on Long Term Survival after Acute Myocardial Infarction in Patients with Diabetes Mellitus’ (1997) 314 BMJ 1512
Marre M and others, ‘Liraglutide, a Once-Daily Human GLP-1 Analogue, Added to a Sulphonylurea over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared with Adding Rosiglitazone or Placebo in Subjects with Type 2 Diabetes (LEAD-1 SU)’ (2009) 26 Diabetic Medicine 268
Marso SP and others, ‘Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes’ [2017] New England Journal of Medicine
Menting JG and others, ‘How Insulin Engages Its Primary Binding Site on the Insulin Receptor’ (2013) 493 Nature 241
Nathan DM and others, ‘Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes’ (2006) 29 Diabetes Care 1963
Nauck M, ‘Incretin Therapies: Highlighting Common Features and Differences in the Modes of Action of Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors’ (2016) 18 Diabetes, Obesity and Metabolism 203
‘New IDegLira Data Show Rapid and Predictable Glycaemic Improvements in People with Type 2 Diabetes’ <http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>
Pickup JC, Reznik Y and Sutton AJ, ‘Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-Analysis and Meta-Regression of Randomized Controlled Trials’ (2017) 40 Diabetes Care 715
‘Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes’ <https://www.youtube.com/watch?v=AhhWTmEFuag>
Raccah D and others, ‘Review of Basal-plus Insulin Regimen Options for Simpler Insulin Intensification in People with Type 2 Diabetes Mellitus’ [2017] Diabetic Medicine
——, ‘Review of Basal-plus Insulin Regimen Options for Simpler Insulin Intensification in People with Type 2 Diabetes Mellitus’ (2017) 34 Diabetic Medicine 1193
Raskin P and others, ‘Initiating Insulin Therapy in Type 2 Diabetes: A Comparison of Biphasic and Basal Insulin Analogs’ (2005) 28 Diabetes Care 260
‘Reduced Weight Gain with Insulin Detemir Compared to NPH Insulin Is Not Explained by a Reduction in Hypoglycemia. - PubMed - NCBI’ <http://www.ncbi.nlm.nih.gov/pubmed/18715200>
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein, Textbook of Diabetes (John Wiley & Sons, Incorporated 2016) <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056&query=#>
Richter B and Neises G, ‘“Human” Insulin versus Animal Insulin in People with Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD003816.pub2>
Riddle MC and others, ‘Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin’ (2013) 36 Diabetes Care 2489
Rodbard HW and others, ‘Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Added to Sulphonylurea Alone or to Sulphonylurea and Metformin in Insulin-Naïve People with Type 2 Diabetes: The DUAL IV Trial’ (2017) 34 Diabetic Medicine 189
Rorsman P and Renstr�m E, ‘Insulin Granule Dynamics in Pancreatic Beta Cells’ (2003) 46 Diabetologia 1029
Rosenstock J and others, ‘A Randomised, 52-Week, Treat-to-Target Trial Comparing Insulin Detemir with Insulin Glargine When Administered as Add-on to Glucose-Lowering Drugs in Insulin-Naive People with Type 2 Diabetes’ (2008) 51 Diabetologia 408
——, ‘Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-Week, Randomized, Open-Label, Active-Controlled Study (GetGoal-X)’ (2013) 36 Diabetes Care 2945
Rosenstock J and others, ‘Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes’ (2014) 37 Diabetes Care 1815
Sharon Allard,Caroline Butler,Sue Cradock,Heather Daly,Jemma Edwards,Elizabeth Gilbert, ‘Using Conversation Maps in Practice: The UK Experience’ (2010) 14 Journal of Diabetes Nursing <http://go.galegroup.com/ps/i.do?id=GALE|A245106172&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=fe5329820c5da4ed2dd0a88a5ced5962>
Srinivasan BT and others, ‘Recent Advances in the Management of Type 2 Diabetes Mellitus: A Review’ (2008) 84 Postgraduate Medical Journal 524
Srinivasan BT and Davies M, ‘Glycaemic Management of Type 2 Diabetes’ (2014) 42 Medicine 711
Swinnen SG and others, ‘Insulin Detemir versus Insulin Glargine for Type 2 Diabetes Mellitus’, Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd 1996) <http://doi.wiley.com/10.1002/14651858.CD006383.pub2>
Villani M, de Courten B and Zoungas S, ‘Emergency Treatment of Hypoglycaemia: A Guideline and Evidence Review’ (2017) 34 Diabetic Medicine 1205
Wahren J and Kallas A, ‘Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes?’ (2012) 61 Diabetes 2228
Walker RA, Rodgers J, and Diabetes UK., Diabetes: A Practical Guide to Managing Your Health (Fully revised and updated, Dorling Kindersley 2010)
Wang W and others, ‘Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis’ [2017] Diabetes Therapy
Yki-Järvinen H and others, ‘Insulin Glargine or NPH Combined with Metformin in Type 2 Diabetes: The LANMET Study’ (2006) 49 Diabetologia 442
Young LA and Buse JB, ‘GLP-1 Receptor Agonists and Basal Insulin in Type 2 Diabetes’ (2014) 384 The Lancet 2180
Zinman B and others, ‘Insulin Degludec, an Ultra-Long-Acting Basal Insulin, Once a Day or Three Times a Week versus Insulin Glargine Once a Day in Patients with Type 2 Diabetes: A 16-Week, Randomised, Open-Label, Phase 2 Trial’ (2011) 377 The Lancet 924
